Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Gammasecretasenotch Signalling Pathway Inhibitor Ro4929097

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00243061Phase 2Completed

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

NCT01120275Phase 2Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Showing all 2 trials

Research Network

Common Treatments

  • Gammasecretasenotch Signalling Pathway Inhibitor Ro49290971
  • Laboratory Biomarker Analysis1
  • Cediranib Maleate1

Active Sponsors

  • National Cancer Institute (NCI)2

Top Investigators

Related Conditions

  • Superficial Spreading Malignant Melanoma2
  • Stage Iv Melanoma2
  • Recurrent Melanoma2
  • Acral Lentiginous Malignant Melanoma2
  • Nodular Malignant Melanoma1

Activity Timeline